open access

Vol 72, No 3 (2022)
Research paper (original)
Published online: 2022-02-11
Get Citation

The prognostic value of RDW, NLR and PLR in sequential radio-chemotherapy for advanced lung cancer

Iwona Jabłońska1, Marcin Miszczyk1, Marcin Goławski2, Iwona Dębosz-Suwińska3, Rafał Suwiński4
·
Nowotwory. Journal of Oncology 2022;72(3):161-166.
Affiliations
  1. IIIrd Radiotherapy and Chemotherapy Clinic and Teaching Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
  2. Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
  3. Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
  4. IInd Radiotherapy and Chemotherapy Clinic and Teaching Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

open access

Vol 72, No 3 (2022)
Original article
Published online: 2022-02-11

Abstract

Introduction.Inflammation plays an important role in carcinogenesis, therefore morphology-based inflammatory indi­ces could be prognostic factors in lung cancer patients. This study aimed to analyze if red cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are associated with patients’ prognosis in non-small cell lung cancer (NSCLC) patients.

Material and methods.The study population included 110 patients treated with definitive sequential radio-chemo­therapy for stage IIIA–IIIB NSCLC. The data were retrospectively analyzed using the receiver operating characteristic (ROC) method, Kaplan-Meier estimator, log-rank testing, and Cox proportional hazards regression model.

Results.The ROC analysis has shown that the optimal cut-off values were 14% for RDW, 2.1 for NLR, and 120 for PLR, with area under the curve (AUC) of 0.606, 0.509, and 0.564 respectively. The overall survival was significantly higher in patients with RDW ≤ 14% with a median survival of 31.2 months compared to 20.2 months for patients with RDW > 14%. RDW was an independent prognostic factor in multivariate analysis.

Conclusions.RDW can provide additional information in assessing patients’ prognosis, but it is necessary to consider its modest sensitivity and specificity. NLR and PLR were not found to be independent prognostic factors.

Abstract

Introduction.Inflammation plays an important role in carcinogenesis, therefore morphology-based inflammatory indi­ces could be prognostic factors in lung cancer patients. This study aimed to analyze if red cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are associated with patients’ prognosis in non-small cell lung cancer (NSCLC) patients.

Material and methods.The study population included 110 patients treated with definitive sequential radio-chemo­therapy for stage IIIA–IIIB NSCLC. The data were retrospectively analyzed using the receiver operating characteristic (ROC) method, Kaplan-Meier estimator, log-rank testing, and Cox proportional hazards regression model.

Results.The ROC analysis has shown that the optimal cut-off values were 14% for RDW, 2.1 for NLR, and 120 for PLR, with area under the curve (AUC) of 0.606, 0.509, and 0.564 respectively. The overall survival was significantly higher in patients with RDW ≤ 14% with a median survival of 31.2 months compared to 20.2 months for patients with RDW > 14%. RDW was an independent prognostic factor in multivariate analysis.

Conclusions.RDW can provide additional information in assessing patients’ prognosis, but it is necessary to consider its modest sensitivity and specificity. NLR and PLR were not found to be independent prognostic factors.

Get Citation

Keywords

lung cancer; red cell distribution width; RDW

About this article
Title

The prognostic value of RDW, NLR and PLR in sequential radio-chemotherapy for advanced lung cancer

Journal

Nowotwory. Journal of Oncology

Issue

Vol 72, No 3 (2022)

Article type

Research paper (original)

Pages

161-166

Published online

2022-02-11

Page views

4967

Article views/downloads

507

DOI

10.5603/NJO.a2022.0010

Bibliographic record

Nowotwory. Journal of Oncology 2022;72(3):161-166.

Keywords

lung cancer
red cell distribution width
RDW

Authors

Iwona Jabłońska
Marcin Miszczyk
Marcin Goławski
Iwona Dębosz-Suwińska
Rafał Suwiński

References (40)
  1. Cancer [Internet]. Geneva: World Health Organisation; 3 Mar 2021. https://www.who.int/news-room/fact-sheets/detail/cancer (19.03.2021).
  2. Cancer A–Z [Internet]. Atlanta: American Cancer Society; c2021. Lung cancer: key statistics for lung cancer; c2021. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html (20.03.2021).
  3. Cancer A–Z [Internet]. Atlanta: American Cancer Society; c2021. Lung cancer: early detection, diagnosis and staging: lung cancer survival rates; c2021. https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html?fbclid=IwAR1XssnYQXP7B_51krxuQPwi_3BCS8x3bmBCZWJ0fiXCjNUQ9QeDUyGjHNY (20.03.2021).
  4. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009; 30(7): 1073–1081.
  5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646–674.
  6. Łochowski M, Chałubińska-Fendler J, et al. Łochowska Prognostic value of red blood cell distribution width-standard deviation (RDW-SD) in patients operated on due to non-small cell lung cancer. J Thorac Dis. 2020; 12: 773–781.
  7. Koma Y, Onishi A, Matsuoka H, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PLoS One. 2013; 8: e80240.
  8. Miszczyk M, Jabłońska I, Magrowski Ł, et al. The association between RDW and survival of patients with squamous cell carcinoma of the tongue. Simple, cheap and convenient? Rep Pract Oncol Radiother. 2020; 25(4): 494–499.
  9. Li J, Yang X, Ma J, et al. Relationship of red blood cell distribution width with cancer mortality in hospital. Biomed Res Int. 2018: 8914617.
  10. Riedl J, Posch F, Königsbrügge O, et al. Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality. PLoS ONE. 2014; 9: e111440.
  11. Wang Y, Zhou Y, Zhou K, et al. Prognostic value of pre-treatment red blood cell distribution width in lung cancer: a meta-analysis. Biomarkers. 2020; 25: 241–247.
  12. Wang PF, Song SY, Guo H, et al. Prognostic role of pretreatment red blood cell distribution width in patients with cancer: A meta-analysis of 49 studies. J Cancer. 2019; 10: 4305–4317.
  13. Hirahara N, Tajima Y, Fuji Y, et al. Comprehensive analysis of red blood cell distribution width as a preoperative prognostic predictor in gastric cancer. Anticancer Res. 2019; 39: 3121–3130.
  14. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005; 91(3): 181–184.
  15. Pryt M, Kalwas M, Nejc D, et al. Can we predict lymph node metastasis by using preoperative markers in gastric cancer patients? Nowotwory J Oncolology. 2019; 69(1): 7–11.
  16. Gomez D, Farid S, Malik HZ, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008; 32(8): 1757–1762.
  17. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008; 34(1): 55–60.
  18. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6): dju124.
  19. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011; 47(17): 2633–2641.
  20. Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009; 197(4): 466–472.
  21. Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014; 23(7): 1204–1212.
  22. Sultana GS, Haque SA, Sultana T, et al. Value of red cell distribution width (RDW) and RBC indices in the detection of iron deficiency anemia. Mymensingh Med J. 2013; 22: 370–376.
  23. Lippi G, Targher G, Montagnana M, et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med. 2009; 133: 628–32.
  24. Bujak K, Wasilewski J, Osadnik T, et al. The prognostic role of red blood cell distribution width in coronary artery disease: a review of the pathophysiology. Dis Markers. 2015; 2015: 1–12.
  25. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001; 102(1): 5–14.
  26. Gomes M, Teixeira AL, Coelho A, et al. The role of inflammation in lung cancer. Adv Exp Med Biol. 2014; 816: 1–23.
  27. Li J, Shen C, Wang X, et al. Prognostic value of TGF-β in lung cancer: systematic review and meta-analysis. BMC Cancer. 2019; 19(1): 691.
  28. Zeni E, Mazzetti L, Miotto D, et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J. 2007; 30(4): 627–632.
  29. De Vita F, Orditura M, Galizia G, et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest. 2000; 117(2): 365–373.
  30. Allen LA, Felker GM, Mehra MR, et al. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail. 2010; 16: 230–238.
  31. Chen J, Wu J, Lv X, et al. The value of red blood cell distribution width, neutrophil-to-lymphocyte ratio, and hemoglobin-to-red blood cell distribution width ratio in the progression of non-small cell lung cancer. PLoS One. 2020; 15: e0237947.
  32. Song B, Shi P, Xiao J, et al. Utility of red cell distribution width as a diagnostic and prognostic marker in non-small cell lung cancer. Sci Rep. 2020; 10: 15717.
  33. Toyokawa G, Shoji F, Yamazaki K, et al. Significance of the red blood cell distribution width in resected pathologic stage I nonsmall cell lung cancer. Semin Thorac Cardiovasc Surg. 2020; 32: 1036–1045.
  34. Ichinose J, Murakawa T, Kawashima M, et al. Prognostic significance of red cell distribution width in elderly patients undergoing resection for non-small cell lung cancer. J Thorac Dis. 2016; 8: 3658–3666.
  35. Kiriu T, Yamamoto M, Nagano T, et al. Prognostic value of red blood cell distribution width in non-small cell lung cancer treated with anti-Programmed Cell Death-1 antibody. In Vivo (Highlands). 2019; 33: 213–220.
  36. Warwick R, Mediratta N, Shackcloth M, et al. Preoperative red cell distribution width in patients undergoing pulmonary resections for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2013; 45: 108–113.
  37. Łaczmańska I, Dębicka I, Gil J, et al. Medycyna personalizowana w raku płuca. Nowotwory J Oncolology. 2021; 71(2): 122–128.
  38. Imfinzi [Internet]. Amsterdam: European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi (21.01.2022).
  39. Krzakowski M, Jassem J, Antczak A, et al. Cancer of the lung, pleura and mediastinum. Oncol Clin Pract. 2019; 15(1).
  40. NCCN Guidelines Version 1.2022 Non-Small Cell Lung Cancer [Internet]. Plymouth Meeting: National Comprehensive Cancer Network; 7 Dec 2021. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 (19.03.2021).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl